Comprehensive expression of long non-coding RNAs and association with iron and erythropoiesis regulatory proteins in transfusion-dependent β-thalassemia

Ola M. Al-Sanabra[1]*, Wafa' J. Haza[2], Abeer A. Haza'a[3], Diya Hasan[4], Mutaz Jamal Al-Khreisat[5], Majd M. Alsaleh[4,6], Ahmad K. Al Tibi[7]

[1]Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Balqa Applied University, Jordan
[2]Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Zhejiang, China
[3]Arkan Laboratory, Zarqa, Jordan
[4]Department of Allied Medical Sciences, Zarqa College, Al-Balqa Applied University, Zarqa, Jordan
[5]Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan
[6]Department of Biology, School of Science, Jordan University, Amman, Jordan
[7]Biolab Diagnostic Laboratories, Amman, Jordan

***Corresponding author:**
Ola M. Al-Sanabra
Department of Medical Laboratory Sciences
Faculty of Allied Medical Sciences
Al-Balqa Applied University, Jordan
E-mail: Ola.Sanabra@bau.edu.jo

Submitted: 12 February 2025; **Accepted:** 1 June 2025
Online publication: 22 June 2025

Arch Med Sci 2025; 21 (6): 2671–2679
DOI: https://doi.org/10.5114/aoms/205790

Abstract

Introduction: β-thalassemia is a genetic disorder characterized by a quantitative defect in β-globin synthesis caused by genetic and epigenetic alterations. However, the expression patterns of *long non-coding RNAs (LncRNAs*) and their relationship with genes and proteins involved in iron metabolism and erythropoiesis remain largely unknown. We aimed to investigate the expression of *LncRNAs* and their correlation with iron and erythropoiesis regulatory proteins in patients with transfusion-dependent β-thalassemia (TDβ-T).

Material and methods: Whole blood samples and clinical records were collected from 60 patients with TDβ-T and 20 healthy controls. Expression levels of selected *LncRNAs* were measured using qRT-PCR. Iron metabolism and erythropoiesis-related proteins were quantified using ELISA.

Results: TDβ-T patients exhibited significantly elevated levels of iron and erythropoiesis regulatory proteins, as well as increased expression of *HAMP*, *GDF-15*, *FAM132B,* and *SLC40A1* compared to controls. Additionally, *LncRNAs ANRIL*, *H19*, *LINCO133*, *MIAT*, and *NEAT1* were markedly upregulated, while *LncRNA GAS5* was downregulated in patients with TDβ-T. Among these, *LncRNAs NEAT1* and *GAS5* showed the strongest diagnostic performance. A significant correlation was observed between the expression of *HAMP* and *FAM132B* and *LncRNAs ANRIL*, *H19, LINCO133*, and *MIAT*. Furthermore, *LncRNA NEAT1* expression correlated positively with *SLC40A1* and negatively with urea levels, whereas *LncRNA GAS5* was inversely correlated with *HAMP* expression.

Conclusions: This study is the first to demonstrate altered *LncRNA* expression patterns and their associations with iron metabolism, erythropoiesis regulatory proteins, and urea levels in patients with TDβ-T. These findings provide new insights for future research and potential therapeutic targets.

Key words: *LncRNA NEAT1*, *LncRNA GAS5*, transfusion-dependent β-thalassemia, iron regulatory proteins erythropoiesis regulatory proteins.

Introduction

β-thalassemia is an autosomal recessive disorder caused by a quantitative defect in β-globin synthesis, leading to impaired hemoglobin production and ineffective erythropoiesis with varying degrees of anemia [1]. Globally, over 30,000 new cases of β-thalassemia cases are reported each year, with the majority occurring in developing countries [2]. Classification of β-thalassemia is based on either the level of β-globin reduction [3] or the necessity for regular blood transfusions [1]. Gene expression and epigenetic regulation play crucial roles in the production of hemoglobin chains, with distinct regulatory mechanisms influencing the pathogenesis of β-thalassemia which exacerbate thalassemia severity and associated complications such as ineffective erythropoiesis and iron overload [1, 4]. Additional contributors to these complications include abnormal regulation of iron metabolism markers like ferritin [5] and hepcidin [6], and erythropoietic regulators such as erythropoietin (EPO) [7], growth differentiation factor 15 (GDF-15) [8], and erythroferrone (ERFE) [9, 10].

Long non-coding RNAs (*LncRNAs*) are emerging as critical regulators in various biological processes, including hematopoiesis. Disruption in *LncRNA* expression has been linked to impaired hemoglobin synthesis and anemia [11]. Recent studies have identified several *LncRNAs* as potential biomarkers or contributors to the pathology of cardiovascular, metabolic, thalassemia and neoplastic diseases. These include antisense non-coding RNA in the INK4 locus (*ANRIL*) [12, 13], growth arrest-specific 5 (*GAS5*) [14], *H19* [15], Metastasis associated lung adenocarcinoma transcript 1 (*MALAT1*) [16], nuclear-enriched abundant transcript 1 (*NEAT1*) [17], and maternally expressed gene 3 (*MEG3*) [18]. Additional *LncRNAs* including *LINC0133*, *SNGH20*, and urothelial carcinoma associated 1 (*UCA1*) are implicated in gene expression regulation in hematological disorders [19]. Despite this growing body of research, the role of LncRNAs in regulating iron metabolism and erythropoiesis in β-thalassemia remains underexplored. To the best of our knowledge, this is the first study to investigate the expression of *LncRNAs* and their correlation with iron and erythropoiesis regulatory proteins in patients with transfusion-dependent-β-thalassemia (TDβ-T). These findings may offer novel insights into disease mechanisms and uncover potential therapeutic targets.

Material and methods

Study design and sample collection

This study was conducted from September 2022 to December 2023 and included 80 participants: 60 patients with TDβ-T and 20 healthy controls. Participants, aged 7–35 years and of both sexes, were recruited from the Department of Thalassemia and Hemophilia at Al-Zarqa Public Hospital, Jordan. Written informed consent was obtained from all participants, and the study was approved by the Institutional Review Board (IRB) of the Ministry of Health, Amman, Jordan.

From each participant, 10 ml of whole blood was collected and divided equally into EDTA and plain tubes. Clinical records were also obtained for all patients with TDβ-T. Blood samples from patients with thalassemia were collected immediately prior to their scheduled blood transfusions.

Quantitation of serum levels of hepcidin, GDF-15, erythropoietin and erythroferrone

Serum levels of hepcidin (Cat. MBS2700551, MyBioSource, USA), GDF-15 (Cat. BMS2258, ThermoFisher Scientific, USA), erythropoietin (Cat. BMS2035-2, ThermoFisher Scientific, USA), and erythroferrone (Cat. EH1681-HS, FineTest Biotech Inc., USA) were quantified using ELISA kits, following the manufacturer's instructions.

Total RNA extraction and cDNA synthesis

Total RNA was extracted from the collected whole blood samples using the Direct-zol RNA Purification Kit (Zymo Research, USA) according to the manufacturer's protocol. RNA purity and concentration were assessed using a NABI spectrophotometer (MicroDigital, Korea). Complementary DNA (cDNA) was synthesized using the PrimeScript™ RT Master Mix Kit (Takara, Japan) following the manufacturer's instructions.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Gene expression was quantified using a QuantGene 9600 thermal cycler (Bioer Technology, Japan) and TB Green® Premix Ex Taq™ _II (Tli RNase H Plus, Japan). Primers were sourced from Integrated DNA Technologies (IDT, Coralville, IA, USA) (Table I). Each qRT-PCR reaction was performed in a 20 µl final volume, containing 2 µl (60 ng) of cDNA, 10 µl of master TB green mix, 2 µl of (10 pmol/µl) primers, and 6 µl of nuclease free water. The thermal cycling conditions consisted of an initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s.

Statistical analysis

Continuous variables were expressed as mean ± standard deviation or median (min.–max.), de-

Table I. Sequences of the qRT-PCR primers

Gene	Forward 3′-5′	Reverse 3′-5′
LncRNA NEAT1	CTTCCTCCCTTTAACTTATCCATTCAC	CTCTTCCTCCACCATTACCAACAATAC
LncRNA LASER	AAGGTGCCACAGATGCTCAA	GGGAGGTATCCCGGAGAAGT
LncRNA MALAT1	GAAGGAAGGAGCGCTAACGA	TACCAACCACTCGCTTTCCC
LncRNA MIAT	TCCCATTCCCGGAAGCTAGA	GAGGCATGAAATCACCCCCA
LncRNA UCA1	ATTAGGCCGAGAGCCGATCA	CCAGAGGAACGGATGAAGCC
LncRNA SNHG20	AGCAACCACTATTTTCTTCC	CCTTGGCGTGTATCTATTTAT
LncRNA H19	TCAGCTCTGGGATGATGTGGT	CTCAGGAATCGGCTCTGGAAG
LncRNA ANRIL	GCCGGACTAGGACTATTTGCC	TGGCATACCACACCCTAAC
LncRNA LINC01133	CCTAATCTCACCACAGCCTGG	TCAGAGGCACTGATGTTGGG
LncRNA MEG3	CTCCCCTTCTAGCGCTCACG	CTAGCCGCCGTCTATACTACCGGCT
LncRNA GAS5	TGTGTCCCCAAGGAAGGATG	TCCACACAGTGTAGTCAAGCC
HAMP	CCTGACCAGTGGCTCTGTTT	CACATCCCACACTTTGATCG
GDF-15	TCAGATGCTCCTGGTGTTGC	GATCCCAGCCGCACTTCTG
FAM132B	GTCCCAGAGTAGGTAGTGAAGA	TCCGGAGGCTAGTTAGTTAGAA
SLC40A1	TCCTTGGCCGACTACCTGAC	TCCCTTTGGATTGTGATTGC
GAPDH	AATGCCTCCTGCACCACCAAC	AAGGCCATGCCAGTGAGCTTC

pending on data distribution. Categorical variables were presented as frequencies (percentages). Fold changes relative to control mean were calculated using the delta-delta C_t method ($2^{-\Delta\Delta Ct}$) and subsequently $\log_2$-transformed to get $\log_2$ fold changes. Differences between patients and controls were assessed using Welch's two-sample *t*-test to account for unequal variances and sample sizes, or the Wilcoxon rank sum test for non-normal distributions. Correlation between $\log_2$ fold changes and other patient clinical parameters was assessed using Spearman correlation. The ability of the differentially expressed *LncRNAs* to distinguish between patients and controls was evaluated using receiver operating characteristic (ROC) curves. Additionally, DeLong test was used to assess if the area under the ROC curve was significantly different from 0.5. All analyses were conducted in R version 4.3.3 (2024-02-29 ucrt).

Results

Demographic characteristics, clinical parameters, and iron metabolism indices of the study population

The mean age and body mass index (BMI) were comparable between groups. Hematological parameters showed significant differences in mean values between the TDβ-T group/patients and controls, except for MCHC (Table II). Furthermore, mean liver enzyme levels were significantly increased in the TDβ-T group/patients compared to controls ($p < 0.0001$). Additionally, the mean urea level was significantly higher ($p = 0.004$), while the mean creatinine level was significantly lower ($p < 0.0001$) in the TDβ-T group (Table II).

Iron-related parameters, including ferritin and serum iron levels, were markedly elevated ($p < 0.001$) in the TDβ-T group/patients compared to controls. No significant difference was observed in the $\log_2$ fold change of *HAMP* expression ($p = 0.16$). In contrast, *GDF-15* expression was significantly upregulated ($p < 0.01$) in TDβ-T, as were *FAM132B* and *SLC40A1* ($p < 0.05$). Hepcidin protein levels did not differ significantly ($p = 0.645$) between patients with TDβ-T and controls. However, the median protein concentrations of GDF-15, ERFF, and EPO were significantly elevated ($p < 0.001$) in the TDβ-T group/patients (Table II).

Differential expression of *long non-coding RNAs* of the study population

LncRNAs *ANRIL* ($p = 0.044$), *H19* ($p = 0.049$), *LINC0133* ($p = 0.047$), *MIAT* ($p = 0.046$), and *NEAT1* ($p < 0.001$) were upregulated on average in patients with TDβ-T compared to controls except for *LncRNA GAS5*, which had a significant ($p < 0.001$) fold downregulation (Table III).

Receiver operating characteristic (ROC) curve analysis

LncRNA NEAT1 and *GAS5* exhibited the highest diagnostic performance with area under the receiver operating characteristic (ROC) curve of 93.5%, and 80.6% respectively, compared to other *LncRNAs* (Table IV, Figure 1).

Table II. Demographic, clinical, iron metabolism and erythropoiesis regulatory protein parameters for the study population

Parameters	Control (*N* = 20)	TDβ-T (*N* = 60)	*P*-value
Demographic			
Age [years]	19.1 ±7	20.2 ±6.9	0.27
BMI [kg/m^2]	21.2 ±1.3	21.5 ±2.6	0.31
Gender:			
Female, *n* (%)	11 (55)	30 (50)	–
Male, *n* (%)	9 (45)	30 (50)	–
Hematological			
Hb [g/dl]	13.5 ±1.6	8.6 ±0.9	***< 0.001
RBC [10^6/µl]	4.7 ±0.5	3.2 ±0.5	***< 0.001
PCV (%)	38.4 ±3.7	24.6 ±2.6	***< 0.001
RDW (%)	13.4 ±1.6	20.1 ±5.3	***< 0.001
MCV [fl]	81.7 ±6.1	77.4 ±6.2	**< 0.01
MCH [pg/l]	28.7 ±3.0	27.0 ±2.8	*< 0.05
MCHC [g/dl]	35.0 ±1.5	34.9 ±1.7	0.672
WBC [10^3/µl]	7.5 ±2.5	15.4 ±6.6	****< 0.0001
Platelets [10^3/µl]	291.1 ±78.9	618.9 ±78.9	****< 0.0001
Biochemical			
ALT [U/l]	12.0 ±4.0	48.2 ±29.6	****< 0.0001
AST [U/l]	18.8 ±6.4	49.7 ±25.3	****< 0.0001
ALP [U/l]	83.6 ±24.1	163.5 ±79.5	****< 0.0001
Urea [mg/l]	22 ±5.4	29.4 ±15.3	**0.004
Creatinine [mg/l]	0.6 ±0.2	0.4 ±0.3	****< 0.0001
Iron metabolism variable			
Ferritin [ng/ml]	36.1 (17.7–165)	2719 (160.0–14658)	***< 0.001
Iron [mg/dl]	84.3 ±22.2	222 ±58.8	***< 0.001
$\log_2$ Δ*HAMP*	–0.0 ±1.5	0.7 ±1.6	0.160
$\log_2$ Δ*GDF-15*	0.0 ±0.9	4.4 ±2.1	**< 0.01
$\log_2$ Δ*FAM132B*	0.0 ±1.2	0.9 ±1.5	*< 0.05
$\log_2$ Δ*SLC40A1*	0.0 ±1.3	0.8 ±1.3	*< 0.05
Hepcidin (pg/mL)	133 (83.1–539)	135 (29.2–337)	0.645
Erythropoiesis regulatory proteins			
GDF-15 [pg/ml]	135 (31–350)	3907 (1276–7090)	***< 0.001
ERFF [pg/ml]	317 (208–1108)	628 (216–1518)	***< 0.001
EPO [mUI/ml]	5.6 (0–27.8)	156 (25.1–667)	***< 0.001

*Numeric variables are summarized as mean ± standard deviation or median (min-max), depending on normality. p-values indicate significance, as determined by Welch's two-sample t-test. Significance levels are represented as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. TDβ-T – transfusion-dependent β-thalassemia, BMI – body mass index, WBC – white blood cells, RBC – red blood cells, PCV – packed cell volume, MCV – mean corpuscular volume, MCH – mean corpuscular hemoglobin, MCHC – mean corpuscular hemoglobin concentration, Hb – hemoglobin, RDW – red cell distribution width, ALT – alanine transaminase, AST – aspartate transaminase, ALP – alkaline phosphates, GDF-15 – growth differentiation factor 15, ERFF – erythroferrone, EPO – erythropoietin.*

Association between *long non-coding RNAs* and iron regulatory proteins in transfusion-dependent β-thalassemia

Log_2 fold changes in *HAMP* and *FAM132B* were strongly and significantly correlated ($p < 0.0001$) with *LncRNA ANRIL*, *LncRNA H19, LncRNA LINCO133*, and *LncRNA MIAT* (Table V, Figures 2 A, C–I). In contrast, *GAS5* expression exhibited a significant negative correlation ($p < 0.05$) with *HAMP* expression (Table V, Figure 2 B). Furthermore, $\log_2$ fold change in *SLC40A1* (encoding ferroportin) positively and markedly ($p < 0.001$) correlated with $\log_2$ fold change in *LncRNA NEAT1* (Table V,

Table III. Mean $\log_2$ fold change of *long non-coding RNAs* expression for the study population

LncRNAs	Mean $\log_2$ fold change relative to controls		Mean fold change relative to controls	*P*-value
	Control (*N* = 20)	TDβ-T (*N* = 60)		
ANRIL	$3.85 \times 10^{-3} \pm 1.4$	1 ±1.4	3.4 ±4.7	**0.044***
GAS5	$-2.75 \times 10^{-3} \pm 1.0$	–2.7 ±4.9	0.6 ±0.8	$2. 10^{-4}$
H19	$6.15 \times 10^{-11} \pm 1.2$	1.0 ±1.7	3.6 ±4.1	**0.049***
LASER	$-2.55 \times 10^{-10} \pm 1.6$	0.6 ±1.6	2.9 ±3.9	0.174
LINC0133	$-2.55 \times 10^{-10} \pm 1.2$	0.8 ±1.4	2.9 ±3.8	**0.047***
MALAT1	$-9.55 \times 10^{-4} \pm 1.5$	0.6 ±1.7	2.8 ±3.2	0.157
MEG3	$-9.75 \times 10^{-4} \pm 1.2$	0.7 ±1.3	2.5 ±3.5	0.095
MIAT	$-1.45 \times 10^{-3} \pm 0.8$	0.8 ±1.8	4.3 ±8.9	**0.046***
NEAT1	$-3.95 \times 10^{-11} \pm 1.0$	3.0 ±1.7	15.3 ±21.6	**< 0.001***
SNGH20	$-2.95 \times 10^{-10} \pm 1.3$	1.1 ±1.6	3.5 ±3.9	0.093
UCA1	0.02 ±1.3	0.1 ±1.4	1.8 ±2.8	0.891

*Numeric variables are summarized as mean ± standard deviation. P-values indicate significance, as determined by Welch's two-sample t-test. Significance levels are represented as follows: *p < 0.05, **p < 0.01, and ***p < 0.001. On log scale, 0 represents no change, negative values represent down-regulation, and positive values represent up-regulation. TDβ-T – transfusion-dependent β-thalassemia.*

Table IV. Diagnostic performance of *long non-coding RNAs* among transfusion-dependent β-thalassemia

$\log_2\Delta$ Target *LncRNAs*	AUC (95% CI)	*P*-value	Specificity	Sensitivity
ANRIL	67.1% (53–81.3%)	**0.020***	38.9%	93.2%
GAS5	80.6% (70.3–91%)	**< 0.0001*****	80%	75%
H19	68.3% (53.3–83.3%)	**0.020***	82%	57%
LINC0133	66% (51.8–80.1%)	**0.030***	61%	73%
MIAT	67.1% (54–80.3%)	**0.013****	93.8%	46.2%
NEAT1	93.5% (87–100%)	**< 0.0001*****	100%	76.9%

*P-values indicate significant as determined by DeLong test. Significance levels are represented as follows: *p < 0.05, **p < 0.01, and ***p < 0.0001. AUC – area under curve, CI – confidence interval.*

Figure 2 J). No significant correlations were observed between the differentially expressed *LncRNAs* and the iron/erythropoiesis regulatory proteins in the control group (data not shown).

Correlation between *long non-coding RNAs* expression, ferritin, and liver/kidney function parameters in transfusion-dependent β-thalassemia

Serum AST and ALT were strongly (rho of 0.55) correlated with ferritin. However, they were not correlated with *LncRNA GAS5* and *LncRNA NEAT1* $\log_2$ fold change/$\log_2$ fold change in *LncRNA GAS5* and *LncRNA NEAT1* except for urea, which was negatively (rho of –0.3) correlated with $\log_2$ fold change of *LncRNA NEAT1* (Table VI).

Discussion

β-thalassemia is a quantitative impairment of β-globin chain biosynthesis caused by genetic and epigenetic aberrations, characterized by ineffective erythropoiesis and a high susceptibility to iron overload [20]. Although few studies have investigated *LncRNA* expression in β-thalassemia [21, 22], none have directly linked these RNAs to their distinguishing clinical features. Our study



Figure 1. Receiver operating characteristic curves analysis of long non-coding RNAs in thalassemia patients

Table V. Correlation between the expression of *long non-coding RNAs* with iron and erythropoiesis regulatory genes and proteins among transfusion-dependent β-thalassemia

$\log_2 \Delta$ *LncRNAs*	*ANRIL*	*GAS5*	*H19*	*LINCO133*	*MIAT*	*NEAT1*
Measured parameters						
Ferritin [ng/ml]	0.02	–0.12	0.06	0.08	–0.04	0.25
Iron [mg/dl]	0.08	–0.02	–0.07	0.16	0.05	0.04
$\log_2 \Delta$ *HAMP*	**0.61****	**–0.38***	**0.56****	**0.58****	**0.59****	0.12
$\log_2 \Delta$ *GDF-15*	–0.21	0.25	–0.19	–0.28	–0.13	0.27
$\log_2 \Delta$ *FAM132B*	**0.64****	**–0.36**	**0.75****	**0.54****	**0.57****	0.17
$\log_2 \Delta$ *SLC40A1*	0.09	0.03	0.04	0.09	0.03	**0.47*****
Hepcidin [pg/ml]	–0.09	0.18	–0.02	–0.02	–0.10	–0.10
GDF-15 [pg/ml]	–0.22	0.20	–0.19	–0.13	–0.05	0.22
ERFF [pg/ml]	–0.12	0.11	0.00	–0.01	0.03	0.22
EPO [mUI/ml]	–0.06	0.06	–0.19	–0.04	–0.06	0.05

*Bold font and stars represent significant correlations. Significance was based on Benjamini-Hochberg adjusted p-values from Spearman correlation. Significance levels are represented as follows: *p < 0.05, ***p < 0.001, ****p < 0.0001. TDβ-T – transfusion-dependent β-thalassemia, GDF-15 – growth differentiation factor 15, ERFF – erythroferrone, EPO – erythropoietin.*

identified a notable reduction in hematological parameters and a significant increase in biochemical markers in patients with TDβ-T compared to controls, consistent with previous findings [23, 24].

We observed a significant ($p < 0.05$) upregulation of genes involved in iron level regulation – *GDF-15*, *ERFE*, and *SLC40A1* – in patients with TDβ-T. Protein levels of GDF-15, ERFF, EPO, ferritin, and serum iron were also significantly ($p < 0.0001$) elevated. Elevated EPO levels stimulate erythropoiesis by promoting the production of ERFE and GDF-15, which subsequently suppresses hepcidin, thereby enhancing iron availability for erythropoiesis [25, 26]. However, we observed no significant difference in hepcidin levels or *HAMP* expression between TDβ-T patients and controls, consistent with some studies [27, 28] but contrasting with



Figure 2. Correlation between $\log_2$ fold changes in long non-coding RNA genes (*x*-axes) and HAMP, ERFE, and SLC40A1 genes (*y*-axes). R: Spearman correlation coefficient



Figure 2. Cont.

Table VI. Correlation of *long non-coding RNAs* expression and ferritin with liver and kidney functions parameters in transfusion-dependent β-thalassemia

Biochemical parameters	$\log_2 \Delta$ *LncRNA GAS5*	$\log_2 \Delta$ *LncRNA NEAT1*	Ferritin [ng/ml]
AST [U/l])	–0.11	0.24	**0.55******
ALT [U/l]	–0.13	0.25	**0.55******
Creatinine [mg/l]	0.07	–0.18	–0.06
Urea [mg/l]	0.17	**–0.30***	–0.15

*Bold font and stars represent significant correlations. Significance was based on Spearman correlation. Significance levels are represented as follows: *p < 0.05, ****p < 0.0001. ALT – alanine transaminase, AST – aspartate transaminase.*

findings by Camaschella *et al.* [26]. This discrepancy may be attributed to variability in transfusion frequency [29], use and type of iron-chelators [30], genetic factors, or inflammatory states. Genetic mutations can worsen or mitigate iron overload, influencing disease severity [31].

LncRNAs are known to disrupt hematopoiesis [19, 32] and hemoglobin production in thalassemia [33]. We observed significant upregulation of *LncRNAs ANRIL, MIAT1,* and *NEAT1,* consistent with Fakhr-Eldeen *et al.* [34], and for the first time, we report the downregulation of *LncRNA GAS5*

and upregulation of *LICN0133 and H19* in TDβ-T patients. ROC analysis identified *LncRNAs NEAT1* and *GAS5* as strong diagnostic biomarkers.

Interestingly, none of the measured proteins–ferritin, hepcidin, GDF-15, ERFE, EPO, or serum iron–correlated significantly with *LncRNA* expression in TDβ-T patients. However, we found strong correlations between TDβ-T *HAMP* and *FAM132B* and *LncRNAs ANRIL*, *H19, LINCO133*, and *MIAT*, representing novel findings. ANRIL is known to influence gene expression involved in metabolic pathways [35], and limited empirical data regarding the roles of *LncRNA H19*, *LncRNA LINC0133*, and *LncRNA MIAT* hampers firm conclusions regarding their roles. Nevertheless, we are at the forefront of research in this area as we are documenting compelling evidence that indicates a robust significant ($p < 0.001$) correlation between *HAMP* and *FAM132B* and *LncRNAs: ANRIL*, *H19*, *LINC0133*, and *MIAT*.

Another pioneering result for this current study was the significant ($p < 0.001$) positive correlation between *LncRNA NEAT1* and *SLC40A1* (encoding ferroportin). While the current body of literature does not explicitly establish a direct association between *LncRNA NEAT1* and *SLC40A1,* the evidenced regulatory functions of *LncRNA NEAT1* within the contexts of oncogenesis and immune system modulation imply that it may exert influence over, or exhibit a correlation with various genes that participate in interconnected biological pathways [36, 37]. Additionally, we are the first to document a significant ($p < 0.05$) negative correlation between *LncRNA GAS5* and *HAMP* expression. This observed inverse relationship can be contextualized within the broader framework of gene expression regulation, while also reflecting the underlying biological implications that negative correlations may signify in various molecular interactions across different pathological conditions, for example, its relationship with HMGB1 in sepsis [38] and with IL-18 in rheumatoid arthritis [39].

Our results showed a robust and significant ($p < 0.001$) correlation between serum AST/ALT and ferritin, aligning with other reports [40, 41]. This reinforces the notion that increased ferritin levels may serve as a biomarker for liver dysfunction specifically among patients with TD-βT. While *GAS5* and *NEAT1* expression showed no significant correlation with liver/kidney function overall, a noteworthy exception was the negative correlation between *NEAT1* and urea levels ($p < 0.05$), which may suggest metabolic regulation, as discussed by Moreno *et al.* [42].

This study has some limitations including a small sample size, lack of analysis across different β-thalassemia phenotypes, and absence of post-transfusion *LncRNA* expression data. Nevertheless, our findings offer novel insights into the molecular landscape of TDβ-T.

In conclusion, to the best of our knowledge, this is the first study to report *LncRNA* alterations in TDβ-T, with *NEAT1* and *GAS5* emerging as promising diagnostic biomarkers. Moreover, the observed association between *LncRNAs* and iron-regulatory and erythropoiesis-related genes warrants further investigation.

Acknowledgments

The authors would like to thank staff of Genetic Company for Biotechnology for their support during conducting this research.

Funding

No external funding.

Ethical approval

Approval number: 13888.

Conflict of interest

The authors declare no conflict of interest.

References

1. Taher AT, Musallam KM, Cappellini MD. Beta-thalassemias. N Engl J Med 2021; 384: 727-43.
2. Hasan D, Al Tibi A, Burghel G, Abdelnour A. Determining the current prevalence of beta-thalassemia variants in Jordan. Arch Med Sci 2023; 19: 523-7.
3. Thein SL. Genetic basis and genetic modifiers of beta-thalassemia and sickle cell disease. Adv Exp Med Biol 2017; 1013: 27-57.
4. Zurlo M, Zuccato C, Cosenza LC, et al. Increased expression of alpha-hemoglobin stabilizing protein (AHSP) mRNA in erythroid precursor cells isolated from beta-thalassemia patients treated with sirolimus (rapamycin). J Clin Med 2024; 13: 2479.
5. Daru J, Colman K, Stanworth SJ, et al. Serum ferritin as an indicator of iron status: what do we need to know? Am J Clin Nutr 2017; 106 (Suppl 6): 1634S-9S.
6. Petrova J, Manolov V, Georgi Dimitrov G, et al. Serum hepcidin levels and stroke in thalassemia patients. Int J Stroke 2016; 11: NP50-1.
7. Fouquet G, Thongsa-Ad U, Lefevre C, et al. Iron-loaded transferrin potentiates erythropoietin effects on erythroblast proliferation and survival: a novel role through transferrin receptors. Exp Hematol 2021; 99: 12-20 e3.
8. Youssry I, Samy RM, AbdelMohsen M, Salama NM. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients. Pediatr Res 2024; 95: 1095-100.
9. Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med 2019; 133: 69-74.
10. Arezes J, Foy N, McHugh K, et al. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood 2020; 135: 547-57.
11. Levin C, Koren A, Rebibo-Sabbah A, et al. Extracellular vesicle MicroRNA that are involved in beta-thalassemia complications. Int J Mol Sci 2021; 22: 9760.

12. Leti F, DiStefano JK. Long noncoding RNAs as diagnostic and therapeutic targets in type 2 diabetes and related complications. Genes (Basel) 2017; 8: 207.
13. Namvar A, Kahaei MS, Fallah H, et al. ANRIL variants are associated with risk of neuropsychiatric conditions. J Mol Neurosci 2020; 70: 212-8.
14. Alharbi KS. Exploring GAS5's impact on prostate cancer: recent discoveries and emerging paradigms. Pathol Res Pract 2023; 251: 154851.
15. Asadi M, Gholampour MA, Kompani F, Alizadeh S. Expression of long non-coding RNA H19 in acute lymphoblastic leukemia. Cell J 2023; 25: 1-10.
16. Li W, Ren Y, Si Y, et al. Long non-coding RNAs in hematopoietic regulation. Cell Regen 2018; 7: 27-32.
17. Zhou W, Qiu K. The correlation between lncRNA NEAT1 and serum hepcidin in the peripheral blood of non-alcoholic fatty liver disease patients. Am J Transl Res 2022; 14: 2593-9.
18. Hussain MS, Majami AA, Ali H, et al. The complex role of MEG3: an emerging long non-coding RNA in breast cancer. Pathol Res Pract 2023; 251: 154850.
19. Le LTT, Nhu CXT. The role of long non-coding RNAs in cardiovascular diseases. Int J Mol Sci 2023; 24: 13805.
20. Gupta R, Musallam KM, Taher AT, Rivella S. Ineffective erythropoiesis: anemia and iron overload. Hematol Oncol Clin North Am 2018; 32: 213-21.
21. Rahaman M, Mukherjee M, Bhattacharya S, et al. Exploring the crosstalk between long non-coding RNAs and microRNAs to unravel potential prognostic and therapeutic biomarkers in beta-thalassemia. Mol Biol Rep 2022; 49: 7057-68.
22. Bao X, Gao Y, Wang Z, et al. Activation of gamma-globin expression by LncRNA-mediated ERF promoter hypermethylation in beta-thalassemia. Clin Epigenet 2024; 16: 12.
23. Karim MF, Ismail M, Hasan AM, Shekhar HU. Hematological and biochemical status of beta-thalassemia major patients in Bangladesh: a comparative analysis. Int J Hematol Oncol Stem Cell Res 2016; 10: 7-12.
24. Saadatifar H, Mard-Soltani M, Niayeshfar A, et al. Correlation between plasma biochemical parameters and cardio-hepatic iron deposition in thalassemia major patients. Scand J Clin Lab Invest 2024; 84: 245-51.
25. Ozturk Z, Gumuslu S, Yalcin K, Kupesiz A. Erythropoiesis and iron parameters in transfusion-dependent and non-transfusion-dependent thalassemias. J Pediatr Hematol Oncol 2021; 43: 186-92.
26. Camaschella C, Pagani A, Silvestri L, Nai A. The mutual crosstalk between iron and erythropoiesis. Int J Hematol 2022; 116: 182-91.
27. Jagadishkumar K, Yerraguntla N, Vaddambal MG. Serum hepcidin levels in children with beta thalassemia major. Indian Pediatr 2018; 55: 911-2.
28. Chauhan R, Sharma S, Chandra J. What regulates hepcidin in poly-transfused beta-thalassemia major: erythroid drive or store drive? Indian J Pathol Microbiol 2014; 57: 39-42.
29. Bhowmik S, Biswas AK, Baranwal AK, et al. The effect of blood transfusion on serum hepcidin levels in chronically transfused patients of beta-thalassemia major: an observational study in a tertiary care centre in Western Maharashtra. Asian J Transfus Sci 2024; 18: 73-8.
30. Premawardhena A, Perera C, Wijethilaka MN, et al. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent beta-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial. BMJ Open 2024; 14: e077342.
31. Tesio N, Bauer DE. Molecular basis and genetic modifiers of thalassemia. Hematol Oncol Clin North Am 2023; 37: 273-99.
32. Cai X, Wang H, Han Y, et al. The essential roles of small non-coding RNAs and RNA modifications in normal and malignant hematopoiesis. Front Mol Biosci 2023; 10: 1176416.
33. Morrison TA, Wilcox I, Luo HY, et al. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis 2018; 69: 1-9.
34. Fakhr-Eldeen A, Toraih EA, Fawzy MS. Long non-coding RNAs MALAT1, MIAT and ANRIL gene expression profiles in beta-thalassemia patients: a cross-sectional analysis. Hematology 2019; 24: 308-17.
35. Pasmant E, Sabbagh A, Vidaud M, Bièche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J 2011; 25: 444-8.
36. Haghighi N, Doosti A, Kiani J. Evaluation of apoptosis, cell proliferation and cell cycle progression by inactivation of the NEAT1 long noncoding RNA in a renal carcinoma cell line using CRISPR/Cas9. Iran J Biotechnol 2023; 21: e3180.
37. Saleh RO, Alkhafaji AT, Mohammed JS, et al. LncRNA NEAT1 in the pathogenesis of liver-related diseases. Cell Biochem Funct 2024; 42: e4006.
38. Zeng Z, Lan Y, Chen Y, et al. LncRNA GAS5 suppresses inflammatory responses by inhibiting HMGB1 release via miR-155-5p/SIRT1 axis in sepsis. Eur J Pharmacol 2023; 942: 175520.
39. Ma C, Wang W, Li P. LncRNA GAS5 overexpression downregulates IL-18 and induces the apoptosis of fibroblast-like synoviocytes. Clin Rheumatol 2019; 38: 3275-80.
40. Al-Moshary M, Imtiaz N, Al-Mussaed E, et al. Clinical and biochemical assessment of liver function test and its correlation with serum ferritin levels in transfusion-dependent thalassemia patients. Cureus 2020; 12: e7574.
41. Pan J, Liao Y, Huang Q, et al. Associations between serum ferritin, iron, and liver transaminases in adolescents: a large cross-sectional study. Nutr Hosp 2023; 40: 949-59.
42. Moreno JA, Hamza e, Guerrero-Hue M, et al. Non-coding RNAs in kidney diseases: the long and short of them. Int J Mol Sci 2021; 22: 6077.